A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial.

MLA

Samaille, Thomas, et al. “A Novel Risk Classification Model Integrating CEA, CtDNA, and PTN Stage for Stage 3 Colon Cancer: A Post Hoc Analysis of the IDEA-France Trial.” Oncologist, vol. 29, no. 11, Nov. 2024, pp. e1492–500. EBSCOhost, https://doi.org/10.1093/oncolo/oyae140.

APA

Samaille, T., Falcoz, A., Cohen, R., Laurent-Puig, P., André, T., Taieb, J., Auclin, E., & Vernerey, D. (2024). A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial. Oncologist, 29(11), e1492–e1500. https://doi.org/10.1093/oncolo/oyae140

Chicago

Samaille, Thomas, Antoine Falcoz, Romain Cohen, Pierre Laurent-Puig, Thierry André, Julien Taieb, Edouard Auclin, and Dewi Vernerey. 2024. “A Novel Risk Classification Model Integrating CEA, CtDNA, and PTN Stage for Stage 3 Colon Cancer: A Post Hoc Analysis of the IDEA-France Trial.” Oncologist 29 (11): e1492–1500. doi:10.1093/oncolo/oyae140.